Humana GLP-1 Prior Authorization Guide: Medicare Part D Coverage, the Weight-Loss Exclusion, and the $50 Medicare GLP-1 Bridge (2026)

In plain English: Humana is overwhelmingly a Medicare insurer, and Medicare Part D is barred by federal law from paying for a GLP-1 used only for weight loss. So a standard Humana Part D or Medicare Advantage (MAPD) plan will not cover Wegovy, Zepbound, or Saxenda for obesity alone. It will cover a GLP-1 through Part D when you have a separate FDA-approved reason — type 2 diabetes (Ozempic, Mounjaro, Rybelsus), cardiovascular-risk reduction (Wegovy), or moderate-to-severe obstructive sleep apnea with obesity (Zepbound) — with prior authorization. And beginning July 1, 2026, eligible Part D members can get a weight-loss GLP-1 for a flat $50 copay through the new, temporary Medicare GLP-1 Bridge, which Humana itself administers nationwide.

Bottom line: what Humana covers (and doesn't)

• Weight loss alone: NOT covered on standard Humana Part D / MAPD plans. The federal Part D statute excludes “agents when used for anorexia, weight loss, or weight gain” — the reason Medicare (including Humana Part D/MAPD) cannot cover GLP-1s for obesity by itself.
• Covered under Part D with PA for a non-obesity indication: type 2 diabetes (Ozempic, Mounjaro, Rybelsus), cardiovascular-risk reduction (Wegovy), and moderate-to-severe obstructive sleep apnea with obesity (Zepbound).
• Medicare GLP-1 Bridge (from July 1, 2026): eligible Part D members can get Wegovy, the Zepbound KwikPen, or Foundayo for weight loss at a $50 copay per 30-day supply — through Dec 31, 2027.
• Humana runs the Bridge for everyone: CMS selected Humana as the nationwide administrator (PA, claims, pharmacy payment) for the Bridge across all Part D plans, not only Humana's own members.
• Humana commercial / employer plans: MAY cover Wegovy or Zepbound for weight loss (typically Tier 3/4 with PA), but this is employer-optional and many plans exclude it. Verify your own plan.

The Medicare GLP-1 Bridge ($50/mo, from July 1 2026)

The Bridge is a temporary, CMS-mandated program that lets Medicare Part D members reach a weight-loss GLP-1 that Part D itself cannot pay for. Key terms:

• Dates: July 1, 2026 through December 31, 2027.
• Drugs included: Foundayo, all Wegovy formulations, and the Zepbound KwikPen.
• Cost: $50 copay per 30-day supply.
• Runs OUTSIDE the Part D benefit: the $50 copay does NOT count toward your deductible or the 2026 $2,100 out-of-pocket cap, and Low-Income Subsidy (LIS) protections do not apply.
• Eligibility tiers (prescriber attestation): BMI ≥ 35; OR BMI ≥ 30 with a qualifying condition (CKD stage 3a or higher, HFpEF, or uncontrolled hypertension on 2+ medications); OR BMI ≥ 27 with prediabetes, prior MI or stroke, or symptomatic peripheral artery disease.
• Who it is NOT for: beneficiaries with type 2 diabetes, obstructive sleep apnea, or MASH — those indications go through regular Part D. You also must not have had GLP-1 Part D coverage in 2023.
• Administered by Humana for all plans: CMS selected Humana to run the Bridge's PA, claims, and pharmacy payment nationwide, for every Part D plan — not just Humana members.

Prior-authorization criteria

• A covered, non-obesity indication is required. Under Part D, Humana can approve a GLP-1 only for an FDA-approved reason other than weight loss: type 2 diabetes (Ozempic, Mounjaro, Rybelsus), cardiovascular-risk reduction (Wegovy), or moderate-to-severe obstructive sleep apnea with obesity (Zepbound).
• Diagnosis documentation. Your prescriber's PA must show the qualifying diagnosis (for example, a type 2 diabetes diagnosis for Ozempic/Mounjaro/Rybelsus, established cardiovascular disease for Wegovy, or an OSA diagnosis with obesity for Zepbound).
• Weight loss alone will be denied. Because the Part D statute excludes agents used for weight loss, a PA that lists obesity as the sole indication cannot be approved on a standard Part D/MAPD plan — the weight-loss path runs through the Bridge instead.
• Bridge PA is separate. A weight-loss GLP-1 sought through the Medicare GLP-1 Bridge uses the Bridge's own prescriber-attestation eligibility (BMI tiers above), handled by Humana as administrator, not the standard Part D PA flow.
• Formulary tiers and step therapy vary by plan. Confirm your specific plan's formulary and any step-therapy requirements before filing.

Why Medicare can't cover weight-loss GLP-1s

“People on Medicare can get GLP-1s covered by Part D plans only if they are used for a medically accepted FDA-approved indication other than obesity, like type 2 diabetes, cardiovascular disease risk reduction, or sleep apnea.”

“The pilot program is not for beneficiaries with type 2 diabetes, obstructive sleep apnea or MASH.”

The first statement is from KFF's analysis of GLP-1 coverage in Medicare and the Medicare GLP-1 Bridge; the second is from AARP's explainer on the Medicare $50 GLP-1 weight-loss copay program. Together they capture the core rule: standard Part D coverage requires a non-obesity indication, and the Bridge exists precisely to reach the beneficiaries a Part D plan cannot — while routing anyone with diabetes, OSA, or MASH back through regular Part D.

How to appeal a Humana Part D denial

Humana Part D denials follow the standard five-level Medicare Part D appeals ladder:

1. Coverage determination. Your prescriber requests the initial decision; Humana must respond within 72 hours (standard) or 24 hours (expedited).
2. Redetermination. If denied, request a redetermination by Humana within 60 days of the denial; the standard decision comes within 7 days.
3. Independent Review Entity (IRE) reconsideration. If Humana upholds the denial, an independent outside reviewer takes the next look.
4. Administrative Law Judge (ALJ) hearing. Escalate to an ALJ if the amount in dispute meets the threshold.
5. Medicare Appeals Council, then federal court. The final two levels of review.

One important routing note: disputes about the Medicare GLP-1 Bridge go through Medicare/CMS rather than the Part D plan's appeals flow, because the Bridge runs outside the Part D benefit.

A caveat on sourcing: Humana.com and the CMS Bridge pages blocked automated retrieval, so the policy here was corroborated through KFF, AARP, and the Medicare Rights Center. The Bridge end date is reported as December 31, 2027 (extended from 2026) — confirm it against the live CMS page — and formulary tiers vary by plan, so always verify your own plan's current terms before filing.

Further reading

• GLP-1 insurance coverage across Medicare, Medicaid, and commercial plans
• Top GLP-1 insurance-coverage questions on Reddit, answered